Biomarkers of tobacco smoke exposure

Advances in Clinical Chemistry

Volumn 67, Issue , 2014, Pages 1-45

  Mattes, William ^a   Yang, Xi ^a   Orr, Michael S ^b   Richter, Patricia ^b   Mendrick, Donna L ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b CENTER FOR TOBACCO PRODUCTS   (United States)

Author keywords

Biomarkers; Biomarkers of exposure; Smoking; Tobacco; Tobacco Control Act

Indexed keywords

BIOLOGICAL MARKER; NICOTINIC RECEPTOR; PASSIVE SMOKING;

ADVERSE EFFECTS; ANALYSIS; BLOOD; CHEMISTRY; DRINKING BEHAVIOR; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION REGULATION; GENETICS; HAIR; HUMAN; NAIL; PASSIVE SMOKING; REPRODUCIBILITY; SMOKING; SPUTUM; TOBACCO; URINE;

ALCOHOL DRINKING; BIOLOGICAL MARKERS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION REGULATION; HAIR; HUMANS; NAILS; RECEPTORS, NICOTINIC; REPRODUCIBILITY OF RESULTS; SMOKING; SPUTUM; TOBACCO; TOBACCO SMOKE POLLUTION;

EID: 84921926487     PISSN: 00652423     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.acc.2014.09.001     Document Type: Chapter

References (210)

1. J. Borio, The Tobacco Timeline, Tobacco News and Information, Tobacco.org. , 2010 (November 22, 2013). http://archive.tobacco.org/History/Tobacco_history.html.
2. Eriksen M., MacKay J., Ross H. The Tobacco Atlas 2012, American Cancer Society, Atlanta. fourth ed.
3. Bonevac D., Lyon P. A Counterblaste to Tobacco-James I, Classical Utilitarianism 2002, University of Texas at Austin, (November 22, 2013). http://www.laits.utexas.edu/poltheory/james/blaste/.
4. Gorgas A.C. Effects of tobacco on youths. Public Health Pap. Rep. 1881, 7:230-240.
5. Dorn H.F. Tobacco consumption and mortality from cancer and other diseases. Public Health Rep. 1959, 74:581-593.
6. United States Department of Health and Human Services, Smoking and Health, United States. Public Health Service. Office of the Surgeon General, 1964.
7. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General 2014, Centers for Disease Control and Prevention (US), Atlanta, GA.
8. World Health Organization WHO Report on the Global Tobacco Epidemic, 2013 2013, WHO Press, Geneva.
9. U.S. 111th Congress, Public Law 111-31: Family Smoking Prevention and Tobacco Control Act, H.R. 1256 2009, U.S. Government Printing Office, Washington.
10. U.S. FDA, Overview of the Family Smoking Prevention and Tobacco Control Act: Consumer fact Sheet, Tobacco Products: Guidance, Regulations & Compliance. 2013 (November 25, 2013).
11. U.S. FDA, Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act, Tobacco Products: Guidance, Regulations & Compliance. 2013 (November 25, 2013).
12. Burns D.M., Anderson C.M., Gray N. Do changes in cigarette design influence the rise in adenocarcinoma of the lung?. Cancer Causes Control 2011, 22:13-22.
13. Dews I. Biomarkers are not new. Biomarkers in Drug Development 2010, 3-14. John Wiley & Sons, Hoboken, NJ. M.R. Bleavins, C. Carini, M. Jurima-Romet, R. Rahbaria (Eds.).
14. Karpetsky T.P., Humphrey R.L., Levy C.C. Influence of renal insufficiency on levels of serum ribonuclease in patients with multiple myeloma. J. Natl. Cancer Inst. 1977, 58:875-880.
15. Biomarkers Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001, 69:89-95.
16. U.S.FDA, Center for Drug Evaluation and Research Drug Development Tools Qualification Program-Clinical Outcome Assessment Qualification Program 2012, U.S. Food and Drug Administration, (January 17, 2012). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284077.html.
17. Aronson J.K. Research priorities in biomarkers and surrogate end-points. Br. J. Clin. Pharmacol. 2012, 73:900-907.
18. Puntmann V.O. How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease. Postgrad. Med. J. 2009, 85:538-545.
19. Stratton K., Shetty P., Wallace R., Bondurant S. Committee to Assess the Science Base for Tobacco Harm Reduction, Clearing the Smoke: Assessing the Science Base for Tobacco Harm Reduction 2001, The National Academies Press, Washington, DC.
20. Committee on Biological Markers of the National Research Council Biological markers in environmental health research. Environ. Health Perspect. 1987, 74:3-9.
21. Mayeux R. Biomarkers: potential uses and limitations. NeuroRx 2004, 1:182-188.
22. Welsh P., Packard C.J., Sattar N. Novel antecedent plasma biomarkers of cardiovascular disease: improved evaluation methods and comparator benchmarks raise the bar. Curr. Opin. Lipidol. 2008, 19:563-571.
23. Montgomery J.E., Brown J.R. Metabolic biomarkers for predicting cardiovascular disease. Vasc. Health Risk Manag. 2013, 9:37-45.
24. Fujisawa K., Katakami N., Kaneto H., Naka T., Takahara M., Sakamoto F., Irie Y., Miyashita K., Kubo F., Yasuda T., Matsuoka T.A., Shimomura I. Circulating soluble RAGE as a predictive biomarker of cardiovascular event risk in patients with type 2 diabetes. Atherosclerosis 2013, 227:425-428.
25. Groenewegen K.H., Postma D.S., Hop W.C., Wielders P.L., Schlosser N.J., Wouters E.F. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008, 133:350-357.
26. Coggon D.I., Martyn C.N. Time and chance: the stochastic nature of disease causation. Lancet 2005, 365:1434-1437.
27. Wang T.J. Multiple biomarkers for predicting cardiovascular events: lessons learned. J. Am. Coll. Cardiol. 2010, 55:2092-2095.
28. Ioannidis J.P., Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Circ. Res. 2012, 110:658-662.
29. Minet E., Cheung F., Errington G., Sterz K., Scherer G. Urinary excretion of the acrylonitrile metabolite 2-cyanoethylmercapturic acid is correlated with a variety of biomarkers of tobacco smoke exposure and consumption. Biomarkers 2011, 16:89-96.
30. Hoffmann D., Adler M., Vaidya V.S., Rached E., Mulrane L., Gallagher W.M., Callanan J.J., Gautier J.C., Matheis K., Staedtler F., Dieterle F., Brandenburg A., Sposny A., Hewitt P., Ellinger-Ziegelbauer H., Bonventre J.V., Dekant W., Mally A. Performance of novel kidney biomarkers in preclinical toxicity studies. Toxicol. Sci. 2010, 116:8-22.
31. Hatsukami D.K., Benowitz N.L., Rennard S.I., Oncken C., Hecht S.S. Biomarkers to assess the utility of potential reduced exposure tobacco products. Nicotine Tob. Res. 2006, 8:600-622.
32. Lee J.W., Devanarayan V., Barrett Y.C., Weiner R., Allinson J., Fountain S., Keller S., Weinryb I., Green M., Duan L., Rogers J.A., Millham R., O'Brien P.J., Sailstad J., Khan M., Ray C., Wagner J.A. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm. Res. 2006, 23:312-328.
33. Swanson B.N. Delivery of high-quality biomarker assays. Dis. Markers 2002, 18:47-56.
34. Burd E.M. Validation of laboratory-developed molecular assays for infectious diseases. Clin. Microbiol. Rev. 2010, 23:550-576.
35. Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General 2010, Centers for Disease Control and Prevention (US), Atlanta, GA.
36. Avila-Tang E., Al-Delaimy W.K., Ashley D.L., Benowitz N., Bernert J.T., Kim S., Samet J.M., Hecht S.S. Assessing secondhand smoke using biological markers. Tob. Control. 2013, 22:164-171.
37. Carmella S.G., Chen M., Han S., Briggs A., Jensen J., Hatsukami D.K., Hecht S.S. Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers. Chem. Res. Toxicol. 2009, 22:734-741.
38. Hecht S.S., Yuan J.M., Hatsukami D. Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention. Chem. Res. Toxicol. 2010, 23:1001-1008.
39. Frost-Pineda K., Liang Q., Liu J., Rimmer L., Jin Y., Feng S., Kapur S., Mendes P., Roethig H., Sarkar M. Biomarkers of potential harm among adult smokers and nonsmokers in the total exposure study. Nicotine Tob. Res. 2011, 13:182-193.
40. Roethig H.J., Munjal S., Feng S., Liang Q., Sarkar M., Walk R.A., Mendes P.E. Population estimates for biomarkers of exposure to cigarette smoke in adult U.S. cigarette smokers. Nicotine Tob. Res. 2009, 11:1216-1225.
41. National Institutes of Health Population Assessment of Tobacco and Health (PATH) 2014, National Institutes of Health, (February 22, 2014). http://www.pathstudyinfo.nih.gov/UI/HomeMobile.aspx.
42. Yan W., Byrd G.D., Ogden M.W. Quantitation of isoprostane isomers in human urine from smokers and nonsmokers by LC-MS/MS. J. Lipid Res. 2007, 48:1607-1617.
43. Minuz P., Patrignani P., Gaino S., Seta F., Capone M.L., Tacconelli S., Degan M., Faccini G., Fornasiero A., Talamini G., Tommasoli R., Arosio E., Santonastaso C.L., Lechi A., Patrono C. Determinants of platelet activation in human essential hypertension. Hypertension 2004, 43:64-70.
44. Sterz K., Scherer G., Ecker J. A simple and robust UPLC-SRM/MS method to quantify urinary eicosanoids. J. Lipid Res. 2012, 53:1026-1036.
45. Richter P.A., Bishop E.E., Wang J., Swahn M.H. Tobacco smoke exposure and levels of urinary metals in the U.S. youth and adult population: the National Health and Nutrition Examination Survey (NHANES) 1999-2004. Int. J. Environ. Res. Public Health 2009, 6:1930-1946.
46. McElroy J.A., Shafer M.M., Trentham-Dietz A., Hampton J.M., Newcomb P.A. Urinary cadmium levels and tobacco smoke exposure in women age 20-69 years in the United States. J. Toxicol. Environ. Health A 2007, 70:1779-1782.
47. Warner J.H., Liang Q., Sarkar M., Mendes P.E., Roethig H.J. Adaptive regression modeling of biomarkers of potential harm in a population of U.S. adult cigarette smokers and nonsmokers. BMC Med. Res. Methodol. 2010, 10:19.
48. Airoldi L., Magagnotti C., Iannuzzi A.R., Marelli C., Bagnati R., Pastorelli R., Colombi A., Santaguida S., Chiabrando C., Schiarea S., Fanelli R. Effects of cigarette smoking on the human urinary proteome. Biochem. Biophys. Res. Commun. 2009, 381:397-402.
49. Schayer S.R., Qu Q., Wang Y., Cohen B.S. 210Pb: a predictive biomarker of retrospective cigarette smoke exposure. Cancer Epidemiol. Biomarkers Prev. 2010, 19:338-350.
50. Yamasaki E., Ames B.N. Concentration of mutagens from urine by absorption with the nonpolar resin XAD-2: cigarette smokers have mutagenic urine. Proc. Natl. Acad. Sci. U.S.A. 1977, 74:3555-3559.
51. DeMarini D.M. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat. Res. 2004, 567:447-474.
52. Pavanello S., Lupi S., Pulliero A., Gregorio P., Saia B.O., Clonfero E. Mutagenic activity of overnight urine from healthy non-smoking subjects. Environ. Mol. Mutagen. 2007, 48:143-150.
53. Mohamadi S., Unyime N., Bao-Zhen Z. Effect of pH on mutagenicity of urine from smokers and nonsmokers. Environ. Toxicol. Pharmacol. 2003, 13:21-27.
54. Rees V.W., Kreslake J.M., O'Connor R.J., Cummings K.M., Parascandola M., Hatsukami D., Shields P.G., Connolly G.N. Methods used in internal industry clinical trials to assess tobacco risk reduction. Cancer Epidemiol. Biomark. Prev. 2009, 18:3196-3208.
55. Varlet V., De Croutte E.L., Augsburger M., Mangin P. A new approach for the carbon monoxide (CO) exposure diagnosis: measurement of total CO in human blood versus carboxyhemoglobin (HbCO). J. Forensic Sci. 2013, 58:1041-1046.
56. Sarkar M., Stabbert R., Kinser R.D., Oey J., Rustemeier K., von Holt K., Schepers G., Walk R.A., Roethig H.J. CYP1A2 and NAT2 phenotyping and 3-aminobiphenyl and 4-aminobiphenyl hemoglobin adduct levels in smokers and non-smokers. Toxicol. Appl. Pharmacol. 2006, 213:198-206.
57. Scherer G., Engl J., Urban M., Gilch G., Janket D., Riedel K. Relationship between machine-derived smoke yields and biomarkers in cigarette smokers in Germany. Regul. Toxicol. Pharmacol. 2007, 47:171-183.
58. Schettgen T., Rossbach B., Kutting B., Letzel S., Drexler H., Angerer J. Determination of haemoglobin adducts of acrylamide and glycidamide in smoking and non-smoking persons of the general population. Int. J. Hyg. Environ. Health 2004, 207:531-539.
59. Bortner J.D., Richie J.P., Das A., Liao J., Umstead T.M., Stanley A., Stanley B.A., Belani C.P., El-Bayoumy K. Proteomic profiling of human plasma by iTRAQ reveals down-regulation of ITI-HC3 and VDBP by cigarette smoking. J. Proteome Res. 2011, 10:1151-1159.
60. Ohlmeier S., Mazur W., Linja-Aho A., Louhelainen N., Ronty M., Toljamo T., Bergmann U., Kinnula V.L. Sputum proteomics identifies elevated PIGR levels in smokers and mild-to-moderate COPD. J. Proteome Res. 2012, 11:599-608.
61. Wang M., Cheng G., Balbo S., Carmella S.G., Villalta P.W., Hecht S.S. Clear differences in levels of a formaldehyde-DNA adduct in leukocytes of smokers and nonsmokers. Cancer Res. 2009, 69:7170-7174.
62. Chen L., Wang M., Villalta P.W., Luo X., Feuer R., Jensen J., Hatsukami D.K., Hecht S.S. Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation. Chem. Res. Toxicol. 2007, 20:108-113.
63. Burger D., Schock S., Thompson C.S., Montezano A.C., Hakim A.M., Touyz R.M. Microparticles: biomarkers and beyond. Clin. Sci. (Lond.) 2013, 124:423-441.
64. Mobarrez F., Antoniewicz L., Bosson J.A., Kuhl J., Pisetsky D.S., Lundback M. The effects of smoking on levels of endothelial progenitor cells and microparticles in the blood of healthy volunteers. PLoS One 2014, 9:e90314.
65. Gordon C., Gudi K., Krause A., Sackrowitz R., Harvey B.G., Strulovici-Barel Y., Mezey J.G., Crystal R.G. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am. J. Respir. Crit. Care Med. 2011, 184:224-232.
66. Badrnya S., Baumgartner R., Assinger A. Smoking alters circulating plasma microvesicle pattern and microRNA signatures. Thromb. Haemost. 2014, 112:128-136.
67. Zhang X., Sebastiani P., Liu G., Schembri F., Dumas Y.M., Langer E.M., Alekseyev Y., O'Connor G.T., Brooks D.R., Lenburg M.E., Spira A. Similarities and differences between smoking-related gene expression in nasal and bronchial epithelium. Physiol. Genomics 2010, 41:1-8.
68. Wistuba I.I., Lam S., Behrens C., Virmani A.K., Fong K.M., LeRiche J., Samet J.M., Srivastava S., Minna J.D., Gazdar A.F. Molecular damage in the bronchial epithelium of current and former smokers. J. Natl. Cancer Inst. 1997, 89:1366-1373.
69. Gower A.C., Steiling K., Brothers J.F., Lenburg M.E., Spira A. Transcriptomic studies of the airway field of injury associated with smoking-related lung disease. Proc. Am. Thorac. Soc. 2011, 8:173-179.
70. Spira A., Schembri F., Beane J., Shah V., Liu G., Brody J.S. Impact of cigarette smoke on the normal airway transcriptome. Chest 2004, 125:115S.
71. Schembri F., Sridhar S., Perdomo C., Gustafson A.M., Zhang X., Ergun A., Lu J., Liu G., Bowers J., Vaziri C., Ott K., Sensinger K., Collins J.J., Brody J.S., Getts R., Lenburg M.E., Spira A. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:2319-2324.
72. Sridhar S., Schembri F., Zeskind J., Shah V., Gustafson A.M., Steiling K., Liu G., Dumas Y.M., Zhang X., Brody J.S., Lenburg M.E., Spira A. Smoking-induced gene expression changes in the bronchial airway are reflected in nasal and buccal epithelium. BMC Genomics 2008, 9:259.
73. Boyle J.O., Gumus Z.H., Kacker A., Choksi V.L., Bocker J.M., Zhou X.K., Yantiss R.K., Hughes D.B., Du B., Judson B.L., Subbaramaiah K., Dannenberg A.J. Effects of cigarette smoke on the human oral mucosal transcriptome. Cancer Prev. Res. (Phila.) 2010, 3:266-278.
74. Bouloukaki I., Tsiligianni I.G., Tsoumakidou M., Mitrouska I., Prokopakis E.P., Mavroudi I., Siafakas N.M., Tzanakis N. Sputum and nasal lavage lung-specific biomarkers before and after smoking cessation. BMC Pulm. Med. 2011, 11:35.
75. Di Giusto E., Eckhard I. Some properties of saliva cotinine measurements in indicating exposure to tobacco smoking. Am. J. Public Health 1986, 76:1245-1246.
76. Machacek D.A., Jiang N.S. Quantification of cotinine in plasma and saliva by liquid chromatography. Clin. Chem. 1986, 32:979-982.
77. Scheidweiler K.B., Marrone G.F., Shakleya D.M., Singleton E.G., Heishman S.J., Huestis M.A. Oral fluid nicotine markers to assess smoking status and recency of use. Ther. Drug Monit. 2011, 33:609-618.
78. Kawada T. Detection limit of saliva cotinine values and statistical validity. Nicotine Tob. Res. 2014, 16:1532.
79. Cheng K., Zhao W., Liu S., Sui G. Microfluidic immunoassay for rapid detection of cotinine in saliva. Biomed. Microdevices 2013, 15:949-957.
80. Etter J.F. Levels of saliva cotinine in electronic cigarette users. Addiction 2014, 109(5):825-829.
81. Sachiyo K., Kumiko A., Keiko N., Kaori K., Sonomi O. Effect of passive smoking using maternal and neonatal salivary cotinine measurements. Nurs. Res. 2012, 61:140-144.
82. Chen H.J., Lin C.R. Noninvasive measurement of smoking-associated N(3)-ethyladenine and N(7)-ethylguanine in human salivary DNA by stable isotope dilution nanoflow liquid chromatography-nanospray ionization tandem mass spectrometry. Toxicol. Lett. 2014, 225:27-33.
83. Chen H.J., Lee C.R. Detection and simultaneous quantification of three smoking-related ethylthymidine adducts in human salivary DNA by liquid chromatography tandem mass spectrometry. Toxicol. Lett. 2014, 224:101-107.
84. Jessie K., Pang W.W., Haji Z., Rahim A., Hashim O.H. Proteomic analysis of whole human saliva detects enhanced expression of interleukin-1 receptor antagonist, thioredoxin and lipocalin-1 in cigarette smokers compared to non-smokers. Int. J. Mol. Sci. 2010, 11:4488-4505.
85. Mueller D.C., Piller M., Niessner R., Scherer M., Scherer G. Untargeted metabolomic profiling in saliva of smokers and nonsmokers by a validated GC-TOF-MS method. J. Proteome Res. 2014, 13:1602-1613.
86. Malerba M., Montuschi P. Non-invasive biomarkers of lung inflammation in smoking subjects. Curr. Med. Chem. 2012, 19:187-196.
87. Comandini A., Rogliani P., Nunziata A., Cazzola M., Curradi G., Saltini C. Biomarkers of lung damage associated with tobacco smoke in induced sputum. Respir. Med. 2009, 103:1592-1613.
88. Pottelberge G.R., Mestdagh P., Bracke K.R., Thas O., Durme Y.M., Joos G.F., Vandesompele J., Brusselle G.G. MicroRNA expression in induced sputum of smokers and patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2011, 183:898-906.
89. Al-Delaimy W.K. Hair as a biomarker for exposure to tobacco smoke. Tob. Control 2002, 11:176-182.
90. Florescu A., Ferrence R., Einarson T., Selby P., Soldin O., Koren G. Methods for quantification of exposure to cigarette smoking and environmental tobacco smoke: focus on developmental toxicology. Ther. Drug Monit. 2009, 31:14-30.
91. Al-Delaimy W.K., Crane J., Woodward A. Is the hair nicotine level a more accurate biomarker of environmental tobacco smoke exposure than urine cotinine?. J. Epidemiol. Community Health 2002, 56:66-71.
92. Al-Delaimy W.K., Mahoney G.N., Speizer F.E., Willett W.C. Toenail nicotine levels as a biomarker of tobacco smoke exposure. Cancer Epidemiol. Biomark. Prev. 2002, 11:1400-1404.
93. Al-Delaimy W.K., Willett W.C. Measurement of tobacco smoke exposure: comparison of toenail nicotine biomarkers and self-reports. Cancer Epidemiol. Biomark. Prev. 2008, 17:1255-1261.
94. Stepanov I., Hecht S.S., Lindgren B., Jacob P., Wilson M., Benowitz N.L. Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine. Cancer Epidemiol. Biomark. Prev. 2007, 16:1382-1386.
95. Brody J.S., Steiling K. Interaction of cigarette exposure and airway epithelial cell gene expression. Annu. Rev. Physiol. 2011, 73:437-456.
96. Khariwala S.S., Hatsukami D., Hecht S.S. Tobacco carcinogen metabolites and DNA adducts as biomarkers in head and neck cancer: potential screening tools and prognostic indicators. Head Neck 2012, 34:441-447.
97. Laterza O.F., Lim L., Garrett-Engele P.W., Vlasakova K., Muniappa N., Tanaka W.K., Johnson J.M., Sina J.F., Fare T.L., Sistare F.D., Glaab W.E. Plasma microRNAs as sensitive and specific biomarkers of tissue injury. Clin. Chem. 2009, 55:1977-1983.
98. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr. Biol. 2002, 12:735-739.
99. Perdomo C., Spira A., Schembri F. MiRNAs as regulators of the response to inhaled environmental toxins and airway carcinogenesis. Mutat. Res. 2011, 717:32-37.
100. Di Leva G., Croce C.M. miRNA profiling of cancer. Curr. Opin. Genet. Dev. 2013, 23:3-11.
101. Banerjee A., Luettich K. MicroRNAs as potential biomarkers of smoking-related diseases. Biomark. Med. 2012, 6:671-684.
102. Mayr M., Zampetaki A., Willeit P., Willeit J., Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler. Thromb. Vasc. Biol. 2013, 33:206-214.
103. Shi Q., Yang X., Mendrick D.L. Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury. Biomark. Med. 2013, 7:307-315.
104. Nair V.S., Maeda L.S., Ioannidis J.P. Clinical outcome prediction by microRNAs in human cancer: a systematic review. J. Natl. Cancer Inst. 2012, 104:528-540.
105. Yuchuan H., Ya D., Jie Z., Jingqiu C., Yanrong L., Dongliang L., Changguo W., Kuoyan M., Guangneng L., Fang X., Lanlan T., Bo Q. Circulating miRNAs might be promising biomarkers to reflect the dynamic pathological changes in smoking-related interstitial fibrosis. Toxicol. Ind. Health 2012, 30:182-191.
106. Doyle T.J., Pinto-Plata V., Morse D., Celli B.R., Rosas I.O. The expanding role of biomarkers in the assessment of smoking-related parenchymal lung diseases. Chest 2012, 142:1027-1034.
107. Planchard D., Loriot Y., Goubar A., Commo F., Soria J.C. Differential expression of biomarkers in men and women. Semin. Oncol. 2009, 36:553-565.
108. Kovalchik S.A., De Matteis S., Landi M.T., Caporaso N.E., Varadhan R., Consonni D., Bergen A.W., Katki H.A., Wacholder S. A regression model for risk difference estimation in population-based case-control studies clarifies gender differences in lung cancer risk of smokers and never smokers. BMC Med. Res. Methodol. 2013, 13:143.
109. Kreuzer M., Boffetta P., Whitley E., Ahrens W., Gaborieau V., Heinrich J., Jockel K.H., Kreienbrock L., Mallone S., Merletti F., Roesch F., Zambon P., Simonato L. Gender differences in lung cancer risk by smoking: a multicentre case-control study in Germany and Italy. Br. J. Cancer 2000, 82:227-233.
110. Zang E.A., Wynder E.L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl. Cancer Inst. 1996, 88:183-192.
111. Wild C.P., Scalbert A., Herceg Z. Measuring the exposome: a powerful basis for evaluating environmental exposures and cancer risk. Environ. Mol. Mutagen. 2013, 54:480-499.
112. Hillemacher T., Frieling H., Moskau S., Muschler M.A., Semmler A., Kornhuber J., Klockgether T., Bleich S., Linnebank M. Global DNA methylation is influenced by smoking behaviour. Eur. Neuropsychopharmacol. 2008, 18:295-298.
113. Launay J.M., Del Pino M., Chironi G., Callebert J., Peoc'h K., Megnien J.L., Mallet J., Simon A., Rendu F. Smoking induces long-lasting effects through a monoamine-oxidase epigenetic regulation. PLoS One 2009, 4:e7959.
114. Joubert B.R., Haberg S.E., Nilsen R.M., Wang X., Vollset S.E., Murphy S.K., Huang Z., Hoyo C., Midttun O., Cupul-Uicab L.A., Ueland P.M., Wu M.C., Nystad W., Bell D.A., Peddada S.D., London S.J. 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy. Environ. Health Perspect. 2012, 120:1425-1431.
115. Boyle P. Cancer, cigarette smoking and premature death in Europe: a review including the Recommendations of European Cancer Experts Consensus Meeting, Helsinki, October 1996. Lung Cancer 1997, 17:1-60.
116. Saha S.P., Bhalla D.K., Whayne T.F., Gairola C. Cigarette smoke and adverse health effects: an overview of research trends and future needs. Int. J. Angiol. 2007, 16:77-83.
117. Health and Human Services NTP 12th report on carcinogens. Rep. Carcinog. 2011, 12:iii-499.
118. Beane J., Vick J., Schembri F., Anderlind C., Gower A., Campbell J., Luo L., Zhang X.H., Xiao J., Alekseyev Y.O., Wang S., Levy S., Massion P.P., Lenburg M., Spira A. Characterizing the impact of smoking and lung cancer on the airway transcriptome using RNA-Seq. Cancer Prev. Res. (Phila.) 2011, 4:803-817.
119. Comandini A., Marzano V., Curradi G., Federici G., Urbani A., Saltini C. Markers of anti-oxidant response in tobacco smoke exposed subjects: a data-mining review. Pulm. Pharmacol. Ther. 2010, 23:482-492.
120. Gerszten R.E., Wang T.J. The search for new cardiovascular biomarkers. Nature 2008, 451:949-952.
121. Goldschmidt-Clermont P.J., Dong C., Seo D.M., Velazquez O.C. Atherosclerosis, inflammation, genetics, and stem cells: 2012 update. Curr. Atheroscler. Rep. 2012, 14:201-210.
122. Sexton K., Balharry D., Brennan P., McLaren J., Brewis I.A., BeruBe K.A. Proteomic profiling of human respiratory epithelia by iTRAQ reveals biomarkers of exposure and harm by tobacco smoke components. Biomarkers 2011, 16:567-576.
123. Talikka M., Sierro N., Ivanov N.V., Chaudhary N., Peck M.J., Hoeng J., Coggins C.R., Peitsch M.C. Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit. Rev. Toxicol. 2012, 42:877-889.
124. Tan X.L., Wang T., Xiong S., Kumar S.V., Han W., Spivack S.D. Smoking-related gene expression in laser capture-microdissected human lung. Clin. Cancer Res. 2009, 15:7562-7570.
125. Vucic E.A., Chari R., Thu K.L., Wilson I.M., Cotton A.M., Kennett J.Y., Zhang M., Lonergan K.M., Steiling K., Brown C.J., McWilliams A., Ohtani K., Lenburg M.E., Sin D.D., Spira A., Macaulay C.E., Lam S., Lam W.L. DNA methylation is globally disrupted and associated with expression changes in COPD small airways. Am. J. Respir. Cell Mol. Biol. 2013.
126. Wang X., Chorley B.N., Pittman G.S., Kleeberger S.R., Brothers J., Liu G., Spira A., Bell D.A. Genetic variation and antioxidant response gene expression in the bronchial airway epithelium of smokers at risk for lung cancer. PLoS One 2010, 5:e11934.
127. Yauk C.L., Lucas Argueso J., Auerbach S.S., Awadalla P., Davis S.R., Demarini D.M., Douglas G.R., Dubrova Y.E., Elespuru R.K., Glover T.W., Hales B.F., Hurles M.E., Klein C.B., Lupski J.R., Manchester D.K., Marchetti F., Montpetit A., Mulvihill J.J., Robaire B., Robbins W.A., Rouleau G.A., Shaughnessy D.T., Somers C.M., Taylor J.G., Trasler J., Waters M.D., Wilson T.E., Witt K.L., Bishop J.B. Harnessing genomics to identify environmental determinants of heritable disease. Mutat. Res. 2013, 752:6-9.
128. Zeskind J.E., Lenburg M.E., Spira A. Translating the COPD transcriptome: insights into pathogenesis and tools for clinical management. Proc. Am. Thorac. Soc. 2008, 5:834-841.
129. Harvey B.G., Strulovici-Barel Y., Vincent T.L., Mezey J.G., Raviram R., Gordon C., Salit J., Tilley A.E., Chung A., Sanders A., Crystal R.G. High correlation of the response of upper and lower lobe small airway epithelium to smoking. PLoS One 2013, 8:e72669.
130. Powell C.A., Spira A., Derti A., DeLisi C., Liu G., Borczuk A., Busch S., Sahasrabudhe S., Chen Y., Sugarbaker D., Bueno R., Richards W.G., Brody J.S. Gene expression in lung adenocarcinomas of smokers and nonsmokers. Am. J. Respir. Cell Mol. Biol. 2003, 29:157-162.
131. Bhutani M., Pathak A.K., Fan Y.H., Liu D.D., Lee J.J., Tang H., Kurie J.M., Morice R.C., Kim E.S., Hong W.K., Mao L. Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in the lungs. Cancer Prev. Res. (Phila.) 2008, 1:39-44.
132. Spivack S.D., Hurteau G.J., Jain R., Kumar S.V., Aldous K.M., Gierthy J.F., Kaminsky L.S. Gene-environment interaction signatures by quantitative mRNA profiling in exfoliated buccal mucosal cells. Cancer Res. 2004, 64:6805-6813.
133. Beane J., Sebastiani P., Liu G., Brody J.S., Lenburg M.E., Spira A. Reversible and permanent effects of tobacco smoke exposure on airway epithelial gene expression. Genome Biol. 2007, 8:R201.
134. Spira A., Beane J., Shah V., Liu G., Schembri F., Yang X., Palma J., Brody J.S. Effects of cigarette smoke on the human airway epithelial cell transcriptome. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:10143-10148.
135. Zhang L., Lee J.J., Tang H., Fan Y.H., Xiao L., Ren H., Kurie J., Morice R.C., Hong W.K., Mao L. Impact of smoking cessation on global gene expression in the bronchial epithelium of chronic smokers. Cancer Prev. Res. (Phila.) 2008, 1:112-118.
136. Chari R., Lonergan K.M., Ng R.T., MacAulay C., Lam W.L., Lam S. Effect of active smoking on the human bronchial epithelium transcriptome. BMC Genomics 2007, 8:297.
137. Shields P.G. Tobacco smoking, harm reduction, and biomarkers. J. Natl. Cancer Inst. 2002, 94:1435-1444.
138. Schmidt C.W. Signs of the times: biomarkers in perspective. Environ. Health Perspect. 2006, 114:A700-A705.
139. Moretto N., Volpi G., Pastore F., Facchinetti F. Acrolein effects in pulmonary cells: relevance to chronic obstructive pulmonary disease. Ann. N. Y. Acad. Sci. 2012, 1259:39-46.
140. Spiess P.C., Deng B., Hondal R.J., Matthews D.E., van der Vliet A. Proteomic profiling of acrolein adducts in human lung epithelial cells. J. Proteomics 2011, 74:2380-2394.
141. Deshmukh H.S., Shaver C., Case L.M., Dietsch M., Wesselkamper S.C., Hardie W.D., Korfhagen T.R., Corradi M., Nadel J.A., Borchers M.T., Leikauf G.D. Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin production. Am. J. Respir. Cell Mol. Biol. 2008, 38:446-454.
142. Deshmukh H.S., McLachlan A., Atkinson J.J., Hardie W.D., Korfhagen T.R., Dietsch M., Liu Y., Di P.Y., Wesselkamper S.C., Borchers M.T., Leikauf G.D. Matrix metalloproteinase-14 mediates a phenotypic shift in the airways to increase mucin production. Am. J. Respir. Crit. Care Med. 2009, 180:834-845.
143. Thompson C.A., Burcham P.C. Genome-wide transcriptional responses to acrolein. Chem. Res. Toxicol. 2008, 21:2245-2256.
144. Steenland K., Thun M. Interaction between tobacco smoking and occupational exposures in the causation of lung cancer. J. Occup. Med. 1986, 28:110-118.
145. Liddell F.D. The interaction of asbestos and smoking in lung cancer. Ann. Occup. Hyg. 2001, 45:341-356.
146. Sethi T.K., El-Ghamry M.N., Kloecker G.H. Radon and lung cancer. Clin. Adv. Hematol. Oncol. 2012, 10:157-164.
147. Lantz P.M., Mendez D., Philbert M.A. Radon, smoking, and lung cancer: the need to refocus radon control policy. Am. J. Public Health 2013, 103:443-447.
148. Morita M., Kumashiro R., Kubo N., Nakashima Y., Yoshida R., Yoshinaga K., Saeki H., Emi Y., Kakeji Y., Sakaguchi Y., Toh Y., Maehara Y. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: epidemiology, clinical findings, and prevention. Int. J. Clin. Oncol. 2010, 15:126-134.
149. Sakata K., Hoshiyama Y., Morioka S., Hashimoto T., Takeshita T., Tamakoshi A. Smoking, alcohol drinking and esophageal cancer: findings from the JACC Study. J. Epidemiol. 2005, 15(Suppl. 2):S212-S219.
150. Castellsague X., Munoz N., De Stefani E., Victora C.G., Castelletto R., Rolon P.A., Quintana M.J. Independent and joint effects of tobacco smoking and alcohol drinking on the risk of esophageal cancer in men and women. Int. J. Cancer 1999, 82:657-664.
151. Toh Y., Oki E., Ohgaki K., Sakamoto Y., Ito S., Egashira A., Saeki H., Kakeji Y., Morita M., Sakaguchi Y., Okamura T., Maehara Y. Alcohol drinking, cigarette smoking, and the development of squamous cell carcinoma of the esophagus: molecular mechanisms of carcinogenesis. Int. J. Clin. Oncol. 2010, 15:135-144.
152. Perkins K.A. The synergistic effect of smoking and serum cholesterol on coronary heart disease. Health Psychol. 1985, 4:337-360.
153. Ge Z., Hao Y., Cao J., Li J., Chen J., Huang J., Wu X., Gu D. Does cigarette smoking exacerbate the effect of blood pressure on the risk of cardiovascular and all-cause mortality among hypertensive patients?. J. Hypertens. 2012, 30:2307-2313.
154. Hung R.J., McKay J.D., Gaborieau V., Boffetta P., Hashibe M., Zaridze D., Mukeria A., Szeszenia-Dabrowska N., Lissowska J., Rudnai P., Fabianova E., Mates D., Bencko V., Foretova L., Janout V., Chen C., Goodman G., Field J.K., Liloglou T., Xinarianos G., Cassidy A., McLaughlin J., Liu G., Narod S., Krokan H.E., Skorpen F., Elvestad M.B., Hveem K., Vatten L., Linseisen J., Clavel-Chapelon F., Vineis P., Bueno-de-Mesquita H.B., Lund E., Martinez C., Bingham S., Rasmuson T., Hainaut P., Riboli E., Ahrens W., Benhamou S., Lagiou P., Trichopoulos D., Holcatova I., Merletti F., Kjaerheim K., Agudo A., Macfarlane G., Talamini R., Simonato L., Lowry R., Conway D.I., Znaor A., Healy C., Zelenika D., Boland A., Delepine M., Foglio M., Lechner D., Matsuda F., Blanche H., Gut I., Heath S., Lathrop M., Brennan P. A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25. Nature 2008, 452:633-637.
155. Thorgeirsson T.E., Geller F., Sulem P., Rafnar T., Wiste A., Magnusson K.P., Manolescu A., Thorleifsson G., Stefansson H., Ingason A., Stacey S.N., Bergthorsson J.T., Thorlacius S., Gudmundsson J., Jonsson T., Jakobsdottir M., Saemundsdottir J., Olafsdottir O., Gudmundsson L.J., Bjornsdottir G., Kristjansson K., Skuladottir H., Isaksson H.J., Gudbjartsson T., Jones G.T., Mueller T., Gottsater A., Flex A., Aben K.K.H., de Vegt F., Mulders P.F.A., Isla D., Vidal M.J., Asin L., Saez B., Murillo L., Blondal T., Kolbeinsson H., Stefansson J.G., Hansdottir I., Runarsdottir V., Pola R., Lindblad B., van Rij A.M., Dieplinger B., Haltmayer M., Mayordomo J.I., Kiemeney L.A., Matthiasson S.E., Oskarsson H., Tyrfingsson T., Gudbjartsson D.F., Gulcher J.R., Jonsson S., Thorsteinsdottir U., Kong A., Stefansson K. A variant associated with nicotine dependence, lung cancer and peripheral arterial disease. Nature 2008, 452:638-642.
156. VanderWeele T.J., Asomaning K., Tchetgen Tchetgen E.J., Han Y., Spitz M.R., Shete S., Wu X., Gaborieau V., Wang Y., McLaughlin J., Hung R.J., Brennan P., Amos C.I., Christiani D.C., Lin X. Genetic variants on 15q25.1, smoking, and lung cancer: an assessment of mediation and interaction. Am. J. Epidemiol. 2012, 175:1013-1020.
157. Bierut L.J. Convergence of genetic findings for nicotine dependence and smoking related diseases with chromosome 15q24-25. Trends Pharmacol. Sci. 2010, 31:46-51.
158. Stevens V.L., Bierut L.J., Talbot J.T., Wang J.C., Sun J., Hinrichs A.L., Thun M.J., Goate A., Calle E.E. Nicotinic receptor gene variants influence susceptibility to heavy smoking. Cancer Epidemiol. Biomark. Prev. 2008, 17:3517-3525.
159. Rodriguez-Antona C., Gomez A., Karlgren M., Sim S.C., Ingelman-Sundberg M. Molecular genetics and epigenetics of the cytochrome P450 gene family and its relevance for cancer risk and treatment. Hum. Genet. 2010, 127:1-17.
160. Bartsch H., Nair U., Risch A., Rojas M., Wikman H., Alexandrov K. Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers. Cancer Epidemiol. Biomark. Prev. 2000, 9:3-28.
161. Hecht S.S. Tobacco smoke carcinogens and lung cancer. J. Natl. Cancer Inst. 1999, 91:1194-1210.
162. Omiecinski C.J., Hassett C., Hosagrahara V. Epoxide hydrolase-polymorphism and role in toxicology. Toxicol. Lett. 2000, 112-113:365-370.
163. Kelada S.N., Eaton D.L., Wang S.S., Rothman N.R., Khoury M.J. The role of genetic polymorphisms in environmental health. Environ. Health Perspect. 2003, 111:1055-1064.
164. Marcus P.M., Hayes R.B., Vineis P., Garcia-Closas M., Caporaso N.E., Autrup H., Branch R.A., Brockmoller J., Ishizaki T., Karakaya A.E., Ladero J.M., Mommsen S., Okkels H., Romkes M., Roots I., Rothman N. Cigarette smoking, N-acetyltransferase 2 acetylation status, and bladder cancer risk: a case-series meta-analysis of a gene-environment interaction. Cancer Epidemiol. Biomark. Prev. 2000, 9:461-467.
165. Marcus P.M., Vineis P., Rothman N. NAT2 slow acetylation and bladder cancer risk: a meta-analysis of 22 case-control studies conducted in the general population. Pharmacogenetics 2000, 10:115-122.
166. Boulton M., Dally J. Biomarkers in oncology drug development. Regul. Rapport. 2010, 7:5-9.
167. Amur S., Frueh F., Lesko L.J., Huang S.-M. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark. Med. 2008, 2:305-311.
168. IARC Working Group on Methods for Evaluating Tobacco Control Policies, Methods for Evaluating Tobacco Control Policies, Tobacco Control Vol 12, International Agency for Research on Cancer, 2008, Lyon.
169. WHO Study Group on Tobacco Product Regulation The scientific basis of tobacco product regulation. WHO Technical Report Series 2007, 112. WHO Press, Geneva, (945). World Health Organization (Ed.).
170. Hatsukami D.K., Giovino G.A., Eissenberg T., Clark P.I., Lawrence D., Leischow S. Methods to assess potential reduced exposure products. Nicotine Tob. Res. 2005, 7:827-844.
171. WHO Study Group on Tobacco Product Regulation The scientific basis of tobacco product regulation. WHO Technical Report Series 2008, 289. WHO Press, Geneva, (951). World Health Organization (Ed.).
172. Lowe F.J., Luettich K., Gregg E.O. Lung cancer biomarkers for the assessment of modified risk tobacco products: an oxidative stress perspective. Biomarkers 2013, 18:183-195.
173. El-Zein R., Vral A., Etzel C.J. Cytokinesis-blocked micronucleus assay and cancer risk assessment. Mutagenesis 2011, 26:101-106.
174. Angerer J., Ewers U., Wilhelm M. Human biomonitoring: state of the art. Int. J. Hyg. Environ. Health 2007, 210:201-228.
175. Wogan G.N. Molecular epidemiology in cancer risk assessment and prevention: recent progress and avenues for future research. Environ. Health Perspect. 1992, 98:167-178.
176. Swenberg J.A., Bordeerat N.K., Boysen G., Carro S., Georgieva N.I., Nakamura J., Troutman J.M., Upton P.B., Albertini R.J., Vacek P.M., Walker V.E., Sram R.J., Goggin M., Tretyakova N. 1,3-Butadiene: biomarkers and application to risk assessment. Chem. Biol. Interact. 2011, 192:150-154.
177. Marano K.M., Naufal Z.S., Kathman S.J., Bodnar J.A., Borgerding M.F., Garner C.D., Wilson C.L. Cadmium exposure and tobacco consumption: biomarkers and risk assessment. Regul. Toxicol. Pharmacol. 2012, 64:243-252.
178. Marano K.M., Naufal Z.S., Kathman S.J., Bodnar J.A., Borgerding M.F., Wilson C.L. Arsenic exposure and tobacco consumption: biomarkers and risk assessment. Regul. Toxicol. Pharmacol. 2012, 64:225-232.
179. Abrams S.M., Mahoney M.C., Hyland A., Cummings K.M., Davis W., Song L. Early evidence on the effectiveness of clean indoor air legislation in New York State. Am. J. Public Health 2006, 96:296-298.
180. Achutan C., West C., Mueller C., Boudreau Y., Mead K. Environmental and Biological Assessment of Environmental Tobacco Smoke Exposure Among Casino Dealers 2009, 39. Health and Human Services, Washington.
181. Repace J.L., Homer M. Laramie, Wyoming Bar Patron Cotinine Study 2005, 14. U.o.W. Wyoming Survey & Analysis Center, Laramie.
182. M. Engelen, M. Farrelly, A. Hyland, The Health and Economic Impact of New York's Clean Indoor Air Act. 2006 (December 5, 2013).
183. Koeter H.B.W.M. Validation: a highly charged concept. Toxicol. In Vitro 1995, 9:851-856.
184. Spielmann H., Liebsch M. Lessons learned from validation of in vitro toxicity test: from failure to acceptance into regulatory practice. Toxicol. In Vitro 2001, 15:585-590.
185. Balls M., Fentem J.H. The validation and acceptance of alternatives to animal testing. Toxicol. In Vitro 1999, 13:837-846.
186. Williams S.A., Slavin D.E., Wagner J.A., Webster C.J. A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nat. Rev. Drug Discov. 2006, 5:897-902.
187. Committee on Qualifications of Biomarkers and Surrogate Endpoints in Chronic Disease 2010, Institute of Medicine, Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease, The National Academies Press.
188. Committee on Scientific Standards for Studies on Modified Risk Tobacco Products, I.o. Medicine, Scientific Standards for Studies on Modified Risk Tobacco Products 2012, The National Academies Press, Washington, DC.
189. Wikipedia Quality Assurance 2014, Wikimedia Foundation, Inc., (February 22, 2014). http://en.wikipedia.org/wiki/Quality_assurance.
190. Gregg E.O., Minet E., McEwan M. Urinary biomarkers of smokers' exposure to tobacco smoke constituents in tobacco products assessment: a fit for purpose approach. Biomarkers 2013, 18:467-486.
191. Chau C.H., Rixe O., McLeod H., Figg W.D. Validation of analytic methods for biomarkers used in drug development. Clin. Cancer Res. 2008, 14:5967-5976.
192. Cummings J., Ward T.H., Greystoke A., Ranson M., Dive C. Biomarker method validation in anticancer drug development. Br. J. Pharmacol. 2008, 153:646-656.
193. Wagner J.A. Strategic approach to fit-for-purpose biomarkers in drug development. Annu. Rev. Pharmacol. Toxicol. 2008, 48:631-651.
194. Goodsaid F.M., Mendrick D.L. Translational medicine and the value of biomarker qualification. Sci. Transl. Med. 2010, 2:47ps44.
195. Sistare F.D., Dieterle F., Troth S., Holder D.J., Gerhold D., Andrews-Cleavenger D., Baer W., Betton G., Bounous D., Carl K., Collins N., Goering P., Goodsaid F., Gu Y.Z., Guilpin V., Harpur E., Hassan A., Jacobson-Kram D., Kasper P., Laurie D., Lima B.S., Maciulaitis R., Mattes W., Maurer G., Obert L.A., Ozer J., Papaluca-Amati M., Phillips J.A., Pinches M., Schipper M.J., Thompson K.L., Vamvakas S., Vidal J.M., Vonderscher J., Walker E., Webb C., Yu Y. Towards consensus practices to qualify safety biomarkers for use in early drug development. Nat. Biotechnol. 2010, 28:446-454.
196. U.S.FDA Critical Path Opportunities List 2006, HHS, (January 28, 2013). http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/CriticalPathOpportunitiesReports/UCM077258.pdf.
197. Merriam-Webster.com Qualify 2013, Merriam-Webster.com, (January 24, 2013). http://www.merriam-webster.com/dictionary/qualify.
198. Wagner J.A., Williams S.A., Webster C.J. Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs. Clin. Pharmacol. Ther. 2007, 81:104-107.
199. Altar C.A., Amakye D., Bounos D., Bloom J., Clack G., Dean R., Devanarayan V., Fu D., Furlong S., Hinman L., Girman C., Lathia C., Lesko L., Madani S., Mayne J., Meyer J., Raunig D., Sager P., Williams S.A., Wong P., Zerba K. A prototypical process for creating evidentiary standards for biomarkers and diagnostics. Clin. Pharmacol. Ther. 2008, 83:368-371.
200. U.S.FDA Guidance for Industry: Qualification Process for Drug Development Tools 2010, (January 28, 2013). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM230597.pdf.
201. U.S.FDA Biomarker qualification context of use 2011, (January 28, 2013). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDevelopmentToolsQualificationProgram/ucm284620.htm.
202. Mattes W.B., Walker E.G., Abadie E., Sistare F.D., Vonderscher J., Woodcock J., Woosley R.L. Research at the interface of industry, academia and regulatory science. Nat. Biotechnol. 2010, 28:432-433.
203. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin. Chem. 1993, 39:561-577.
204. Jafarzadeh S.R., Johnson W.O., Utts J.M., Gardner I.A. Bayesian estimation of the receiver operating characteristic curve for a diagnostic test with a limit of detection in the absence of a gold standard. Stat. Med. 2010, 29:2090-2106.
205. Cook N.R. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 2007, 115:928-935.
206. Cook N.R. Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve. Clin. Chem. 2008, 54:17-23.
207. Soreide K. Receiver-operating characteristic curve analysis in diagnostic, prognostic and predictive biomarker research. J. Clin. Pathol. 2009, 62:1-5.
208. Subtil F., Pouteil-Noble C., Toussaint S., Villar E., Rabilloud M. A simple modeling-free method provides accurate estimates of sensitivity and specificity of longitudinal disease biomarkers. Methods Inf. Med. 2009, 48:299-305.
209. Taylor J.M., Ankerst D.P., Andridge R.R. Validation of biomarker-based risk prediction models. Clin. Cancer Res. 2008, 14:5977-5983.
210. Vickers A.J., Cronin A.M., Elkin E.B., Gonen M. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med. Inform. Decis. Mak. 2008, 8:53.